News & Events

News

Cytavis Starts Phase II Clinical Trial with Aviscumine in Metastatic Colorectal Carcinoma Patients

Hamburg/Germany, September 14, 2009 – Cytavis GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced the start of a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma (NCT 00932724)

Phase II trial with Aviscumine (CY-503): Metastatic Melanoma

CYTAVIS BioPharma is currently conducting a phase II trial with Aviscumine (CY-503) in patients with metastatic melanoma (stage IV).

Events

There are no events for this month.